Anna Bordelon, MD
Ophthalmology · Durham, NCNPI 1831356716
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,000 of the $1,084 with a category attached, or 92.2%. Johnson & Johnson Surgical Vision, Inc. accounts for 92.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $1,026 and has fallen 96.9% since, to $32 in 2022. That places this record below the midpoint for ophthalmology clinicians in NC, where the typical reported total is $1,378.
Across 7 payments — averaging $154.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$1K
- Carl Zeiss Meditec Cataract Technology Inc.$44
- Ocular Therapeutix, Inc.$26
- Glaukos Corporation$11
- Notal Vision, Inc.$3
What the payments were for
- Consulting fees$1,00092%
- Speaking & faculty fees$30%
- Food & beverage$817%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 1 | $1,000 |
| Carl Zeiss Meditec Cataract Technology Inc. | 2 | $44 |
| Ocular Therapeutix, Inc. | 2 | $26 |
| Glaukos Corporation | 1 | $11 |
| Notal Vision, Inc. | 1 | $3 |
How this compares
$1,084 in reported general payments places this provider in the 40th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 170 | $162,667 |
| XiidraLifitegrast | 62 | $70,194 |
| Cyclosporine | 68 | $38,648 |
| Prednisolone Acetate | 185 | $5,342 |
| Latanoprost | 161 | $1,651 |
| Brimonidine Tartrate | 41 | $598 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 15 | $542 |
| Timolol Maleate | 15 | $531 |
| ValacyclovirValacyclovir Hcl | 13 | $329 |
| Ketorolac Tromethamine | 22 | $318 |
| ErythromycinErythromycin Base | 23 | $307 |
| Ofloxacin | 28 | $278 |
| Acyclovir | 14 | $176 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $172 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Durham
- Julie WoodwardDurham$1M
- Lejla VajzovicDurham$681K
- Terry KimDurham$605K
- Leon HerndonDurham$230K
- Glenn JaffeDurham$218K
- Robin VannDurham$213K
- Anthony KuoDurham$186K
- Michael RichardDurham$113K
- Priyatham MettuDurham$111K
- Jason LissDurham$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.